NASDAQ: PRPH - ProPhase Labs, Inc.

Rentabilität für sechs Monate: -87.77%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan ProPhase Labs, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen ProPhase Labs, Inc.

ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

weitere details
The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 1997-01-16
ISIN US74345W1080
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 0.3
Сайт https://www.prophaselabs.com
Цена ао 0.48
Preisänderung pro Tag: -3.45% (0.3015)
Preisänderung pro Woche: +16.44% (0.25)
Preisänderung pro Monat: -25.85% (0.3926)
Preisänderung über 3 Monate: -51.92% (0.6055)
Preisänderung über sechs Monate: -87.77% (2.38)
Preisänderung pro Jahr: -95.27% (6.155)
Preisänderung über 3 Jahre: -96.41% (8.1)
Preisänderung über 5 Jahre: -86.14% (2.1)
Preisänderung seit Jahresbeginn: -58.12% (0.6951)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 1.8 8
P/BV 1.62 8
P/E 9.69 9
EV/EBITDA -6.64 0
Gesamt: 7.75

Effizienz

Name Bedeutung Grad
ROA, % -18.26 0
ROE, % -33.98 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0.7 7
Gesamt: 3.43

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.875 10
Gesamt: 9.8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 348.32 10
Rentabilität Ebitda, % 429.54 10
Rentabilität EPS, % 274.4 10
Gesamt: 10
Weitere Details

Institutionen Volumen Aktie, %
Vanguard Group Inc 609347 3.38
Renaissance Technologies, LLC 245710 1.36
HighTower Advisors, LLC 173124 0.96
Geode Capital Management, LLC 137409 0.76
Perritt Capital Management, Inc. 85900 0.48
Blackrock Inc. 60754 0.34
SVB Wealth LLC 47665 0.26
Northern Trust Corporation 45962 0.25
Bank Of New York Mellon Corporation 42531 0.24
State Street Corporation 40163 0.22



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Ted William Karkus Chairman & CEO 902.2k 1959 (66 Jahre)
Mr. Sergio Miralles Executive VP & Chief Information Officer N/A
Mr. Kamal Obbad Senior VP and Director of Sales & Marketing - Nebula Genomics N/A
Mr. Jason Karkus President of Nebula Genomics N/A
Mr. Jed A. Latkin Chief Operating Officer & Head of Finance Department N/A 1974 (51 Jahr)
Mr. Lance Bisesar Corporate Controller

Adresse: United States, Garden City. NY, 711 Stewart Avenue - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.prophaselabs.com